SCHEMBL1840182

SCHEMBL1840182

COc1cc(CN2Cc3c(-c4ccccc4)ccnc3OCC2=O)cc(OC)c1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.54
FPR1 P21462 1/20 0.54
GPR183 P32249 1/20 0.54
APLNR P35414 1/20 0.54
GLP1R P43220 1/20 0.54
GPBAR1 Q8TDU6 1/20 0.54
GPR35 Q9HC97 1/20 0.54
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
HCRTR1 O43613 1/20 0.41
GAA P10253 1/20 0.41
PTGER2 P43116 1/20 0.40
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838901 0.89 ADRB2 (0.56) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL1953463 0.83 ADRB2 (0.59) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL1952769 0.83 ADRB2 (0.64) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL1833669 0.82 GPBAR1 (0.79) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL1837176 0.81 PTGER2 (0.46) MEN1KMT2APTGER2ALDH1A1CYP3A4
SCHEMBL1833564 0.80 ADRB2 (0.47) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL1834372 0.79 GPBAR1 (0.77) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL1834658 0.79 ADRB2 (0.54) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL1833589 0.78 ADRB2 (0.55) ADRB2FPR1GPR183APLNRGLP1R
SCHEMBL6793053 0.77 ROCK2 (0.42) MEN1KMT2AALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130281435-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2013-10-24 US disclosed
US-20110136788-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-09 US disclosed
EP-2322222-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME Takeda Pharmaceutical Company Limited (JP) 2011-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136788-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME GPBAR1, GPR35, GRPR ADRB2 173/4885FPR1 363/4885GPR183 110/4885
US-20130281435-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME GPBAR1, GPR35, GRPR ADRB2 187/4885FPR1 426/4885GPR183 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.